Nishant Tiwari Reports Zero Relapses with Scheduled Rituximab in TTP
Nishant Rajendra Tiwari, Hematology-Oncology Fellow at OU Health Stephenson Cancer Center, posted on X:
”Pre-emptive rituximab stopped relapses in our iTTP patients.
After 3-5 prior relapses each and 1 exacerbation, 4 patients received scheduled Rituximab for 2 years.
Result? No relapses during a median 17.5-month follow-up. (Range 3 – 68 months)
This is a big deal for a tough disease. Grateful to my mentor, Dr. Khawandanah and our team. More studies are needed, but hope is here.
Super thankful to all of our mentor – Dr James N George, truly a difference maker in these patients, and in his mentees’ careers.
The fellows at OU Health Stephenson Cancer Center continue to shine; we have the best leadership and the fellowship program director (Dr. Sami Ibrahimi).”
Keep up with Hemostasis Today.
-
Jun 24, 2026, 17:04Recurrent Cervical Internal Carotid Vasospasm Linked to Autosomal Recessive PTGIS Defect – International Journal of Stroke
-
Jun 24, 2026, 16:49Gaurav Kharya: Bridging the Gap in Safe Blood Access for Patients Who Can’t Wait
-
Jun 24, 2026, 16:40William Wallace: Vitamin C and Collagen Work as One Biological System
-
Jun 24, 2026, 16:32Arlindo Nascimento de Lemos Junior: Thrombus Echogenicity as a Predictor of Post-Thrombotic Syndrome Severity After DVT
-
Jun 24, 2026, 16:09Jimi Olaghere: The Future of Sickle Cell Disease Research Starts With Collaboration
-
Jun 24, 2026, 16:03Von Willebrand Disease as a Common Yet Under-Recognised Bleeding Disorder – EHC
-
Jun 24, 2026, 15:57Maia Meier: Women with Bleeding Disorders Reach the Summit of Mont Blanc
-
Jun 24, 2026, 15:40Annette Bowyer: The Emerging Role of Extravascular Factor VII in Haemostasis
-
Jun 24, 2026, 13:50Tijjani Balas: Why Early Detection of DVT Matters